Royan Institute
Tehran, Iran
NCT Number: NCT02134132
Diabetes is a multiorgan disease and considered a major health problem in different societies. One of the complications the pain particularly in the extremities resulting from a process known as diabetic foot ulcer. The diabetic patients are subjected to many complications because of foot ulcers, many of them like as chronic wound disease or pressure ulcers (bed sore). Routinely used medical measures for diabetic foot ulcers are depended to nursing care and take too long until pain relief. Among many tested materials and works for wound healing such as debridement, tissue oxygenation, and skin transplantation, platelet-derived compounds are allocated the pivotal position between investigators to tissue regeneration and shortening the wound healing process.
Many of platelet components are procured from platelet rich plasma (PRP) from whole blood donation. Furthermore, it requires to an additional purification step to diminish the volume and facilitate handling in some studies. It means that platelet concentrates (PCs) may be obtained leading to more concentrated platelets in lower volume.
Two types of granules in platelet is responsible for storage of many useful and different growth factors: dense or delta and alpha granules. Platelet-derived growth factors have the ability to growth and differentiation of numerous cells. Also, the antibacterial effect of these growth factors has been reported.
To better efficacy and comfortable utilization of platelet, it is feasible to form the platelet gel and then apply on wound sites.
This study is a double blind randomized controlled trial to evaluate the positive effects of umbilical cord blood-derived platelet gel in 244 patients with diabetic foot ulcers.
Looking for future studies?
Notify Me30 year–65 year
All sexes
Interventional
Phase 1 / Phase 2
Tehran, Iran
In this study all qualified patients (based on the inclusion and exclusion criteria) were randomly allocated into three study groups by a Stratified Permuted Block randomization method: group A received platelet rich plasma gel, group B (placebo) received platelet poor plasma gel, and group C received lubricant gel.
All of the patients underwent a standard long protocol for knee osteoarthritis. All patients with diabetic foot ulcer are selected.On average,in each instance, the amount of platelets in the peripheral bloodis4 to6 times the baseline level.
Group A (interventional): application of 20-30mL of gel from platelet rich plasma (PRP) Group B (placebo): application of 20-30mL of gel from platelet poor plasma (PRP) Group C (control): application of 20-30 mL of lubricant gel (used typically for sonography)
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Application of platelet gel in patients suffering from diabetic foot ulcers.
The patients with Diabetic foot ulcer who receive placebo instead of PL Gel.
Time frame: 3 months
Evaluation the pain reduction by VAS measurement in patients with peripheral artery Disease.
Time frame: 3 months
Evaluation the Ankle Brakial Index (ABI) in patients 3 months after PG utilization.
Time frame: 3months
Evaluation the quality of life by SF36 measurement in patients with PAD.
Royan Institute
Other Gov
Utilization of Umbilical Cord Blood-derived Platelet Gel for Treatment of Diabetic Foot Ulcers,a Randomized Double Blind Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07602491
Cardiovascular Diseases, Diabetes Complications
Cairo, Egypt
View Trial DetailsNCT07432581
Cardiovascular Diseases, Diabetes Complications
Cairo, Egypt
View Trial DetailsNCT01070433
Cardiovascular Diseases, Diabetes Complications
Phoenix, Arizona, United States
View Trial DetailsNCT01154374
Cardiovascular Diseases, Diabetes Complications
New Haven, Connecticut, United States
View Trial Details